Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow, Sheena Bhalla, Mary Beth Beasley, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 345-362
Closed Access | Times Cited: 1046

Showing 1-25 of 1046 citing articles:

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Andrew G. Nicholson, Ming‐Sound Tsao, Mary Beth Beasley, et al.
Journal of Thoracic Oncology (2021) Vol. 17, Iss. 3, pp. 362-387
Open Access | Times Cited: 890
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Giampaolo Bianchini, Carmine De Angelis, Luca Licata, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 91-113
Closed Access | Times Cited: 787
Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3044-3060
Open Access | Times Cited: 721
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 492
NF-κB in biology and targeted therapy: new insights and translational implications
Qing Guo, Yizi Jin, Xinyu Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 394
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 287
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
R. Vanguri, Jia Luo, Andrew Aukerman, et al.
Nature Cancer (2022) Vol. 3, Iss. 10, pp. 1151-1164
Open Access | Times Cited: 189
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Antonio Passaro, Julie R. Brahmer, Scott Antonia, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 6, pp. 598-610
Closed Access | Times Cited: 184
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 2, pp. 114-131
Open Access | Times Cited: 141
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Joseph J. Zhao, Dominic Wei Ting Yap, Yiong Huak Chan, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 4, pp. 392-402
Open Access | Times Cited: 134
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 134
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen Chen, Zehua Wang, Yi Ding, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 127
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1617-1635
Open Access | Times Cited: 127
Heterogeneity of the tumor immune microenvironment and its clinical relevance
Qingzhu Jia, Aoyun Wang, Yixiao Yuan, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 122
Precision treatment in advanced hepatocellular carcinoma
Xupeng Yang, Chen Yang, Shu Zhang, et al.
Cancer Cell (2024) Vol. 42, Iss. 2, pp. 180-197
Open Access | Times Cited: 118
Mesenchymal Stem Cell‐Derived Extracellular Vesicles with High PD‐L1 Expression for Autoimmune Diseases Treatment
Fang Xu, Ziying Fei, Huaxing Dai, et al.
Advanced Materials (2021) Vol. 34, Iss. 1
Closed Access | Times Cited: 117
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Liping Pei, Yang Liu, Lin Liu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 113
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino‐Kenudson, Kurt A. Schalper, Wendy A. Cooper, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 12, pp. 1335-1354
Open Access | Times Cited: 112
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Alice Tison, Soizic Garaud, Laurent Chiche, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 11, pp. 641-656
Closed Access | Times Cited: 100
Versatility of bacterial outer membrane vesicles in regulating intestinal homeostasis
Xinyue Wang, Sisi Lin, Lu Wang, et al.
Science Advances (2023) Vol. 9, Iss. 11
Open Access | Times Cited: 97
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 6, pp. 440-462
Closed Access | Times Cited: 96
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal, Amy Prawira, Scott Antonia, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e004424-e004424
Open Access | Times Cited: 96
Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 94
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 92
Page 1 - Next Page

Scroll to top